BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

880 related articles for article (PubMed ID: 23299969)

  • 1. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis.
    Bechmann LP; Kocabayoglu P; Sowa JP; Sydor S; Best J; Schlattjan M; Beilfuss A; Schmitt J; Hannivoort RA; Kilicarslan A; Rust C; Berr F; Tschopp O; Gerken G; Friedman SL; Geier A; Canbay A
    Hepatology; 2013 Apr; 57(4):1394-406. PubMed ID: 23299969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease.
    Aguilar-Olivos NE; Carrillo-Córdova D; Oria-Hernández J; Sánchez-Valle V; Ponciano-Rodríguez G; Ramírez-Jaramillo M; Chablé-Montero F; Chávez-Tapia NC; Uribe M; Méndez-Sánchez N
    Ann Hepatol; 2015; 14(4):487-93. PubMed ID: 26019035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The intrahepatic expression levels of bile acid transporters are inversely correlated with the histological progression of nonalcoholic fatty liver disease.
    Okushin K; Tsutsumi T; Enooku K; Fujinaga H; Kado A; Shibahara J; Fukayama M; Moriya K; Yotsuyanagi H; Koike K
    J Gastroenterol; 2016 Aug; 51(8):808-18. PubMed ID: 26601667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trimethylamine N-Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease.
    Tan X; Liu Y; Long J; Chen S; Liao G; Wu S; Li C; Wang L; Ling W; Zhu H
    Mol Nutr Food Res; 2019 Sep; 63(17):e1900257. PubMed ID: 31095863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editor's Highlight: Clofibrate Decreases Bile Acids in Livers of Male Mice by Increasing Biliary Bile Acid Excretion in a PPARα-Dependent Manner.
    Zhang Y; Lickteig AJ; Csanaky IL; Klaassen CD
    Toxicol Sci; 2017 Dec; 160(2):351-360. PubMed ID: 28973556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. n-3 Fatty Acids Abrogate Dyslipidemia-Induced Changes in Bile Acid Uptake, Synthesis, and Transport in Young and Aged Dyslipidemic Rats.
    Acharya P; Talahalli RR
    Lipids; 2019 Jan; 54(1):39-51. PubMed ID: 30740707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The fate of fatty liver disease: of bile and fatty acids.
    Grünhage F; Lammert F
    Ann Hepatol; 2013; 12(4):642-3. PubMed ID: 23813144
    [No Abstract]   [Full Text] [Related]  

  • 8. Critical illness evokes elevated circulating bile acids related to altered hepatic transporter and nuclear receptor expression.
    Vanwijngaerden YM; Wauters J; Langouche L; Vander Perre S; Liddle C; Coulter S; Vanderborght S; Roskams T; Wilmer A; Van den Berghe G; Mesotten D
    Hepatology; 2011 Nov; 54(5):1741-52. PubMed ID: 21800341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bile acids contribute to the development of non-alcoholic steatohepatitis in mice.
    Gillard J; Clerbaux LA; Nachit M; Sempoux C; Staels B; Bindels LB; Tailleux A; Leclercq IA
    JHEP Rep; 2022 Jan; 4(1):100387. PubMed ID: 34825156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Muricholic bile acids are potent regulators of bile acid synthesis via a positive feedback mechanism.
    Hu X; Bonde Y; Eggertsen G; Rudling M
    J Intern Med; 2014 Jan; 275(1):27-38. PubMed ID: 24118394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice.
    Rao A; Kosters A; Mells JE; Zhang W; Setchell KD; Amanso AM; Wynn GM; Xu T; Keller BT; Yin H; Banton S; Jones DP; Wu H; Dawson PA; Karpen SJ
    Sci Transl Med; 2016 Sep; 8(357):357ra122. PubMed ID: 27655848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease.
    Ma H; Gomez V; Lu L; Yang X; Wu X; Xiao SY
    J Gastroenterol Hepatol; 2009 Feb; 24(2):233-7. PubMed ID: 18713296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adiponectin inhibits steatotic CD95/Fas up-regulation by hepatocytes: therapeutic implications for hepatitis C.
    Wedemeyer I; Bechmann LP; Odenthal M; Jochum C; Marquitan G; Drebber U; Gerken G; Gieseler RK; Dienes HP; Canbay A
    J Hepatol; 2009 Jan; 50(1):140-9. PubMed ID: 19019483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apoptosis is associated with CD36/fatty acid translocase upregulation in non-alcoholic steatohepatitis.
    Bechmann LP; Gieseler RK; Sowa JP; Kahraman A; Erhard J; Wedemeyer I; Emons B; Jochum C; Feldkamp T; Gerken G; Canbay A
    Liver Int; 2010 Jul; 30(6):850-9. PubMed ID: 20408954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bile acid promotes liver regeneration via farnesoid X receptor signaling pathways in rats.
    Ding L; Yang Y; Qu Y; Yang T; Wang K; Liu W; Xia W
    Mol Med Rep; 2015 Jun; 11(6):4431-7. PubMed ID: 25634785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver.
    Zollner G; Wagner M; Fickert P; Geier A; Fuchsbichler A; Silbert D; Gumhold J; Zatloukal K; Kaser A; Tilg H; Denk H; Trauner M
    Am J Physiol Gastrointest Liver Physiol; 2005 Nov; 289(5):G798-805. PubMed ID: 16002565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D receptor activation down-regulates the small heterodimer partner and increases CYP7A1 to lower cholesterol.
    Chow EC; Magomedova L; Quach HP; Patel R; Durk MR; Fan J; Maeng HJ; Irondi K; Anakk S; Moore DD; Cummins CL; Pang KS
    Gastroenterology; 2014 Apr; 146(4):1048-59. PubMed ID: 24365583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How adiponectin, leptin, and ghrelin orchestrate together and correlate with the severity of nonalcoholic fatty liver disease.
    Machado MV; Coutinho J; Carepa F; Costa A; Proença H; Cortez-Pinto H
    Eur J Gastroenterol Hepatol; 2012 Oct; 24(10):1166-72. PubMed ID: 22735605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fetuin-A mRNA expression is elevated in NASH compared with NAFL patients.
    Kahraman A; Sowa JP; Schlattjan M; Sydor S; Pronadl M; Wree A; Beilfuss A; Kilicarslan A; Altinbaş A; Bechmann LP; Syn WK; Gerken G; Canbay A
    Clin Sci (Lond); 2013 Oct; 125(8):391-400. PubMed ID: 23627434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atorvastatin induces bile acid-synthetic enzyme Cyp7a1 by suppressing FXR signaling in both liver and intestine in mice.
    Fu ZD; Cui JY; Klaassen CD
    J Lipid Res; 2014 Dec; 55(12):2576-86. PubMed ID: 25278499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.